Last $9.96 USD
Change Today -0.12 / -1.19%
Volume 635.7K
ACRX On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 8:10 PM 07/22/14 All times are local (Market data is delayed by at least 15 minutes).

acelrx pharmaceuticals inc (ACRX) Snapshot

Open
$10.18
Previous Close
$10.08
Day High
$10.28
Day Low
$9.92
52 Week High
03/6/14 - $13.64
52 Week Low
10/31/13 - $6.04
Market Cap
432.0M
Average Volume 10 Days
845.6K
EPS TTM
$-0.52
Shares Outstanding
43.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ACELRX PHARMACEUTICALS INC (ACRX)

Related News

No related news articles were found.

acelrx pharmaceuticals inc (ACRX) Related Businessweek News

No Related Businessweek News Found

acelrx pharmaceuticals inc (ACRX) Details

AcelRx Pharmaceuticals, Inc., a development stage specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute and breakthrough pain (BTP). Its principal product candidate is Zalviso, an investigational pre-programmed, non-invasive, handheld system that has completed Phase III clinical trials for the treatment of moderate-to-severe acute pain in adult patients in the hospital setting. The company is also developing ARX-04, a Sufentanil Single-Dose NanoTab, which has completed Phase II clinical trials for the treatment of moderate-to-severe acute pain to be administered by a healthcare professional to a patient in settings of acute pain, such as on the battlefield, in the emergency room, or in ambulatory care facilities. In addition, its product candidate pipeline consists of ARX-02, a Sufentanil NanoTab pain management system, which has completed Phase II clinical trials for the treatment of cancer patients who suffer from breakthrough pain (BTP); and ARX-03, a Sufentanil/Triazolam NanoTab, a Phase II clinical trials completed product designed to provide mild sedation, anxiety reduction, and pain relief for patients undergoing painful procedures in a physician’s office. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.

30 Employees
Last Reported Date: 05/8/14
Founded in 2005

acelrx pharmaceuticals inc (ACRX) Top Compensated Officers

Chief Executive Officer, President, Chief Com...
Total Annual Compensation: $475.0K
Co-Founder, Chief Medical Officer and Directo...
Total Annual Compensation: $409.0K
Chief Engineering Officer
Total Annual Compensation: $301.0K
Chief Development Officer
Total Annual Compensation: $292.8K
Compensation as of Fiscal Year 2013.

acelrx pharmaceuticals inc (ACRX) Key Developments

AcelRx Pharmaceuticals, Inc. Presents at BIO International Convention, Jun-26-2014 11:30 AM

AcelRx Pharmaceuticals, Inc. Presents at BIO International Convention, Jun-26-2014 11:30 AM. Venue: San Diego Convention Center, San Diego, California, United States.

AcelRx Pharmaceuticals, Inc. Presents at ROTH Healthcare Corporate Access Day - London, Jun-24-2014

AcelRx Pharmaceuticals, Inc. Presents at ROTH Healthcare Corporate Access Day - London, Jun-24-2014 . Venue: The Dorchester, 3 Tilney Street, London, W1K 1BJ, United Kingdom.

AcelRx Pharmaceuticals, Inc. Announces Executive Changes

AcelRx Pharmaceuticals, Inc. announced that David Chung has resigned as Chief Commercial Officer in order to assume the role of Chief Executive Officer of a medical device company. Richard King, the Company's President and Chief Executive Officer, will assume the duties and responsibilities of the Chief Commercial Officer, and will lead the continued build-out of the commercial organization and launch preparation for Zalviso until a suitable replacement is found. Mr. King has served as a director, president and chief executive officer for AcelRx since May 2010.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ACRX:US $9.96 USD -0.12

ACRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ACRX.
View Industry Companies
 

Industry Analysis

ACRX

Industry Average

Valuation ACRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 15.2x
Price/Book 6.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 11.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACELRX PHARMACEUTICALS INC, please visit www.acelrx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.